Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amedisys (AMED) stocks in Canada

Learn how to easily invest in Amedisys stocks.

Amedisys is a medical care facilities business based in the US. Amedisys stocks (AMED.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $270.32 – a decrease of 1.44% over the previous week. Amedisys employs 21,000 staff and has a trailing 12-month revenue of around $2.2 billion.

How to buy shares in Amedisys

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMED – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Amedisys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Amedisys's stock price?

Since the stock market crash in March caused by coronavirus, Amedisys's stock price has had significant negative movement.

Its last market close was $146.79, which is 24.35% down on its pre-crash value of $194.03 and 10.41% up on the lowest point reached during the March crash when the stocks fell as low as $132.9495.

If you had bought $1,000 worth of Amedisys stocks at the start of February 2020, those stocks would have been worth $938.56 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $819.09.

Amedisys stock price (NASDAQ:AMED)

Use our graph to track the performance of AMED stocks over time.

Amedisys shares at a glance

Information last updated 2022-01-10.
Latest market close$146.79
52-week range$133.62 - $325.12
50-day moving average $162.92
200-day moving average $209.84
Wall St. target price$204.07
PE ratio 22.3686
Dividend yield N/A (0%)
Earnings per share (TTM) $6.66

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Amedisys price performance over time

Historical closes compared with the close of $146.79 from 2022-01-14

1 week (2022-01-05) N/A
1 month (2021-12-16) -3.62%
3 months (2021-10-12) N/A
6 months (2021-07-16) -43.20%
1 year (2021-01-15) -50.05%
2 years (2020-01-16) -19.04%
3 years (2019-01-16) 16.04%
5 years (2017-01-13) 233.77%

Is Amedisys under- or over-valued?

Valuing Amedisys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amedisys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amedisys's P/E ratio

Amedisys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Amedisys shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Amedisys's PEG ratio

Amedisys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8044. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amedisys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Amedisys's EBITDA

Amedisys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $296.6 million.

The EBITDA is a measure of a Amedisys's overall financial performance and is widely used to measure a its profitability.

Amedisys financials

Revenue TTM $2.2 billion
Operating margin TTM 12.06%
Gross profit TTM $911.2 million
Return on assets TTM 9.39%
Return on equity TTM 25.99%
Profit margin 9.98%
Book value $27.78
Market capitalisation $4.9 billion

TTM: trailing 12 months

Amedisys share dividends

We're not expecting Amedisys to pay a dividend over the next 12 months.

Have Amedisys's shares ever split?

Amedisys's shares were split on a 4:3 basis on 5 December 2006. So if you had owned 3 shares the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Amedisys shares – just the quantity. However, indirectly, the new 25% lower share price could have impacted the market appetite for Amedisys shares which in turn could have impacted Amedisys's share price.

Amedisys share price volatility

Over the last 12 months, Amedisys's shares have ranged in value from as little as $133.62 up to $325.12. A popular way to gauge a stock's volatility is its "beta".

AMED.US volatility(beta: 0.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amedisys's is 0.6893. This would suggest that Amedisys's shares are less volatile than average (for this exchange).

Amedisys overview

Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site